Cargando…

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers

Triple negative breast cancer (TNBC) represent 15% of breast cancers. Histoclinical features and marketed prognostic gene expression signatures (GES) failed to identify good- and poor-prognosis patients. Tyrosine kinases (TK) represent potential prognostic and/or therapeutic targets for TNBC. We sou...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Nonneville, Alexandre, Finetti, Pascal, Adelaide, José, Lambaudie, Éric, Viens, Patrice, Gonçalves, Anthony, Birnbaum, Daniel, Mamessier, Emilie, Bertucci, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721506/ https://www.ncbi.nlm.nih.gov/pubmed/31412533 http://dx.doi.org/10.3390/cancers11081158

Ejemplares similares

WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2021)

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
por: Bertucci, François, et al.
Publicado: (2023)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression
por: Boudin, Laurys, et al.
Publicado: (2022)

Kinome expression profiling and prognosis of basal breast cancers
por: Sabatier, Renaud, et al.
Publicado: (2011)

The MonarchE trial: improving the clinical outcome in HR(+)/HER2(−) early breast cancer: recent results and next steps
por: Bertucci, François, et al.
Publicado: (2023)

Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype
por: de Nonneville, Alexandre, et al.
Publicado: (2023)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
por: Bertucci, François, et al.
Publicado: (2018)

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

Validation and comparison of the molecular classifications of pancreatic carcinomas
por: Birnbaum, David J., et al.
Publicado: (2017)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
por: Sabatier, Renaud, et al.
Publicado: (2014)

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
por: Bertucci, François, et al.
Publicado: (2021)

A seven-gene prognostic model for platinum-treated ovarian carcinomas
por: Sabatier, R, et al.
Publicado: (2011)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
por: Goncalves, Anthony, et al.
Publicado: (2021)

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease
por: Mari, Roxane, et al.
Publicado: (2019)

Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?
por: Aulas, Anaïs, et al.
Publicado: (2020)

The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

Comparative genomic analysis of primary tumors and metastases in breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients
por: Lopresti, Alexia, et al.
Publicado: (2022)

Low cholesterol biosynthesis favors epithelial‐to‐mesenchymal transition maintenance and influences tumor molecular subtyping and disease‐free survival in colon cancer patients
por: Aulas, Anaïs, et al.
Publicado: (2022)

8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer
por: Bertucci, François, et al.
Publicado: (2012)

A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases
por: Tyran, Marguerite, et al.
Publicado: (2019)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
por: Bertucci, François, et al.
Publicado: (2020)

Loss, mutation and deregulation of L3MBTL4 in breast cancers
por: Addou-Klouche, Lynda, et al.
Publicado: (2010)

A 25-gene classifier predicts overall survival in resectable pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2017)

PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
por: Birnbaum, David Jeremie, et al.
Publicado: (2023)

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers
por: Monneur, Audrey, et al.
Publicado: (2017)

“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity
por: Mamessier, Emilie, et al.
Publicado: (2012)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes
por: Bekhouche, Ismahane, et al.
Publicado: (2011)

Prognostic value of PDL1 expression in pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2016)

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer
por: Guerin, Mathilde, et al.
Publicado: (2018)

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
por: Mogenet, Alice, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b2o1s2lij3mdkaukob057a6uk3